"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Jazz Pharmaceuticals has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary ...

The genomic medicine space has seen incredible success, but investors are overlooking it. For once, it’s not efficacy that’s ...

23andMe is currently trading at around $3.15, down from more than $18 at the start of the year and more than $200 on its ...

Pelacarsen is in a cardiovascular outcomes trial in patients with elevated Lp (a) levels, with results expected in 2025, ...

The company made its debut last year with a $51 million Series A and a licensing agreement with Astellas for a gene therapy ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

US President-Elect Donald Trump is reported to be considering the nomination of Johns Hopkins surgeon and writer Martin Makary to lead the FDA after he takes office in January. The rumour was ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

DXPs can now eliminate swivel chair processes. Commercial organisations can integrate existing systems with a DXP and have ...

Researchers from the National Institutes of Health (NIH) are applying artificial intelligence to the recruitment of ...

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the ...